Abstract:Background: Inherited medullary thyroid carcinoma (MTC) is primarily caused by RET mutations that are commonly localized in exons 5, 8, 10, 11, and 13-16. In this study, we report pedigrees for individuals with MTC that harbor a germline S409Y variant within exon 6 of the RET proto-oncogene. Methods: Targeted sequencing was used to diagnose four apparently sporadic MTC index cases carrying the germline RET S409Y (c.1226 C>A) variant. Subsequently, 27 relatives of these individuals underwent clinical and genetic assessments and/or thyroid surgery. Furthermore, in silico analyses and in vitro assays were performed to predict or verify the potential oncogenic activity of the S409Y variant. Results: Overall, 15 of 31 participants were found to carry the RET S409Y variant. Of these, 6 presented with isolated MTC (mean age 50.2 years; range 41-75 years), of which 3 presented with neck lymph node metastases and 2 presented with distant liver or lung metastases. Among the remaining 9 carriers, 3 (mean age 56 years; range 41-76 years) had elevated serum calcium-stimulated calcitonin (sCtn) or concurrent marginally elevated serum calcitonin (Ctn) levels, whereas the other 6 (mean age 37.5 years; range 14-52 years) exhibited typical Ctn/sCtn levels (p < 0.05). None of the 15 carriers in these 4 families presented clinical evidence of pheochromocytoma, hyperparathyroidism, or Hirschsprung's disease. In silico analyses revealed that S409Y was a "possibly damaging" mutation that could affect the RET protein inter-domain interface. An in vitro assay revealed that the phosphorylation level of RET tyrosine 905 was relatively higher in the RET S409Y mutant than in wild-type (WT) RET. Moreover, transfection of HEK 293 cells with S409Y enhanced the phosphorylation activity of AKT, ERK pathways, and it increased cell proliferation compared with WT RET, but to a lesser degree than that for the RET C618Y and C634Y mutations. Conclusions: This study demonstrates that the novel germline RET S409Y variant is likely pathogenic and is associated with lower penetrance of MTC than that for the C618Y and C634Y mutations. Individuals with S409Y should be managed using a personalized approach, and additionally, "at-risk" family members should be evaluated. Additional studies are needed to elucidate the correlation between the S409Y mutation and multiple endocrine neoplasia type 2-specific tumors.

Emergence of teicoplanin resistance during therapy of Staphylococcus aureus endocarditis.

Genotype-specific development of MEN 2 constituent components in 683 RET carriers

RET S409Y Germline Mutation and Associated Medullary Thyroid Carcinoma.

MEN2 phenotype in a family with germline heterozygous rare RET K666N variant

The clinical patterns and RET proto-oncogene in fifteen multiple endocrine neoplasia type 2A pedigrees]

C634Y mutation in RET -induced multiple endocrine neoplasia type 2A: A case report

Preimplantation Genetic Diagnosis of Multiple Endocrine Neoplasia Type 2A Using Informative Markers Identified by Targeted Sequencing.

RET 634 germline/gonadal mosaicism generating a second pathogenic amino acid change in multiple endocrine neoplasia type 2A

Ret Proto-Oncogene Mutations Are Restricted To Codons 634 And 918 In Mainland Chinese Families With Men2a And Men2b

[Primary structure of Escherichia coli RNA-polymerase. Nucleotide sequence of gene rpoB and amino acid sequence of the beta-subunit].

RET Germline Mutations Identified by Exome Sequencing in a Chinese Multiple Endocrine Neoplasia Type 2a/familial Medullary Thyroid Carcinoma Family.

Update on Multiple Endocrine Neoplasia Type 2: Focus on Medullary Thyroid Carcinoma

Difference in development of medullary thyroid carcinoma among carriers of RET mutations in codons 790 and 791

A novel mutation (D631del) of the RET gene was associated with MEN2A in a Chinese pedigree.

Integrated filters for telecommunications

RET c.1901G>A and Novel SLC12A3 Mutations in Familial Pheochromocytomas

Does Genotype-Specific Phenotype in Patients with Multiple Endocrine Neoplasia Type 2 Occur as Current Guidelines Predict?

RET Proto-Oncogene Genetic Screening of Families with Multiple Endocrine Neoplasia Type 2 Optimizes Diagnostic and Clinical Management in China.

p.L105Vfs mutation in a family with thymic neuroendocrine tumor combined with MEN1: a case report

Multiple Endocrine Neoplasia Type 2A Caused by a P.c618r RET Proto-Oncogene Mutation in a Chinese Pedigree

Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype